Nearly 1.3 million Americans 12 and older abuse prescription drugs and require treatment for their problem, a new study concludes. Older
The U.S. Food and Drug Administration (FDA) has announced a joint public meeting of the agency's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee to be held February
Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metas
Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra (Meningococcal [Groups A, C, Y and W-
FDA has approved Apokyn (apomorphine) as an injectable drug for treating Parkinson's patients during episodes of "hypomobility," so-called "off periods" in which the patient becomes
New analysis from Frost & Sullivan,
Altana AG has announced that Alvesco (Ciclesonide), a novel inhaled corticosteroid (ICS) for the treatment of adults (18+ years) suffering from persistent asthma is now available for the first time in t
Last Friday an FDA expert panel voted overwhelmingly against the over-the-counter sale of Merck's cholesterol lowering drug Mevacor (lovastatin). Mevacor is one of a number of drugs known as "statins" which are widely considered to be the most effectiv
Patients and researchers will be able to look at data on the safety of different medicines announced Health Minister, Lord Warner today. The move is part of a series of measures to further improve the drug side effect reporting system - the
ALTANA AG has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted ALTANA Pharma marketing a
Both studies are randomized, double-blind, placebo-controlled, dose-ranging, multi-national, multi-center trials, with the goal of obtaining substantial evidence of safety and efficacy for their respective indications.
The company also announced that it will establish two subsidiary companies: one in Germany to manage clinical studies in European countries and a second in the United States. Establishment of these subsidiaries will enable the company to take a vital step towards its planned full-scale global drug development. Y's Therapeutics also expects these operations to include business development and non-clinical & clinical development functions, as well as in-house lab function capability to enhance drug development.
"We recognized early on the importance of designing and conducting clinical trials on a very broad scale," stated Mr. Masanori Murayama, Co-founder, President and CEO of Y's Therapeutics. "By establishing a global clinical network, we can optimize and accelerate the clinical proof of concept stage for the drugs in development."
YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
YSTH2 is a small-molecule drug in development for treatment of asthma and other diseases in which Th-2 type cytokine imbalance is suspected. The molecule works by inhibiting T-cell proliferation and migration, and by inhibiting Th-2 type and proinflammatory cytokine production, while exerting no effect on Th-1 type cytokine production.
http://www.ysthera.com/